A Novel Botulinum Toxin TAT-EGFP-HCS Fusion Protein Capable of Specific Delivery Through the Blood-brain Barrier to the Central Nervous System.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- A Novel Botulinum Toxin TAT-EGFP-HCS Fusion Protein Capable of Specific Delivery Through the Blood-brain Barrier to the Central Nervous System.
- Published In:
- CNS & neurological disorders drug targets, 18(1), 37-43 (2019)
- Authors:
- Hao, Fengjin, Feng, Yueqin, Guan, Yifu
- Database ID:
- RPEP-04222
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-04222APA
Hao, Fengjin; Feng, Yueqin; Guan, Yifu. (2019). A Novel Botulinum Toxin TAT-EGFP-HCS Fusion Protein Capable of Specific Delivery Through the Blood-brain Barrier to the Central Nervous System.. CNS & neurological disorders drug targets, 18(1), 37-43. https://doi.org/10.2174/1871527317666181011113215
MLA
Hao, Fengjin, et al. "A Novel Botulinum Toxin TAT-EGFP-HCS Fusion Protein Capable of Specific Delivery Through the Blood-brain Barrier to the Central Nervous System.." CNS & neurological disorders drug targets, 2019. https://doi.org/10.2174/1871527317666181011113215
RethinkPeptides
RethinkPeptides Research Database. "A Novel Botulinum Toxin TAT-EGFP-HCS Fusion Protein Capable ..." RPEP-04222. Retrieved from https://rethinkpeptides.com/research/hao-2019-a-novel-botulinum-toxin
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.